Peer-reviewed veterinary case report
Treatment outcomes for cats with nasal planum cancer using Sr90
By Berlato, Davide et al.·Published in Journal of feline medicine and surgery·2019·Oncology Unit, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Response, disease-free interval and overall survival of cats with nasal planum squamous cell carcinoma treated with a fractionated vs a single-dose protocol of strontium plesiotherapy.
- Species:
- cat
Plain-English summary
A group of 74 cats with nasal planum squamous cell carcinoma (a type of skin cancer on the nose) received treatment with strontium plesiotherapy, either in a single dose or in multiple smaller doses. The treatment was successful, with 74% of the cats showing complete response, and the average time without disease recurrence was about 780 days. Cats treated with the fractionated approach had a longer disease-free interval compared to those who received a single dose, but overall survival rates were similar for both groups. The treatment was found to be safe with minimal side effects, and most cats had a good cosmetic outcome after treatment.
People also search for: cat nose cancer treatment · squamous cell carcinoma in cats · strontium plesiotherapy for cats · cat skin cancer survival rate
Abstract
OBJECTIVES: The main aim of the study was to establish response, disease-free interval (DFI) and overall survival of cats with nasal planum squamous cell carcinoma (SCC) treated with Sr90 plesiotherapy. A secondary aim was to determine whether a fractionated protocol is more effective than a single-dose protocol in terms of response, DFI and overall survival. The third aim was to evaluate whether we can identify prognostic factors that influence overall survival. METHODS: This was a retrospective study that included cats with a diagnosis of nasal planum SCC treated with Sr90 plesiotherapy at a single institution. RESULTS: Seventy-four cats were included in the study. Thirty-two were treated with a fractionated protocol and 42 with a single-dose treatment. Sr90 plesiotherapy was able to induce complete response in 74% of cats with nasal planum SCC. The median DFI was 780 days (95% confidence interval [CI] 383-1177), with 17% of cats experiencing local recurrence. The overall survival for all cats was 1039 days (95% CI 55-1528). The DFI of cats treated with the fractionated Sr90 was significantly longer compared with the single-dose treatment, whereas response and overall survival were not statistically different. Other prognostic factors that influenced the overall survival were early-stage disease, absence of concurrent problems and complete response to the treatment. Acute and long-term toxicity associated with the treatment were minimal and the aesthetic outcome was pleasing in almost all cases. CONCLUSIONS AND RELEVANCE: Strontium plesiotherapy is a safe and effective treatment of nasal planum SCC in cats.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29788830/